The Amanta Healthcare IPO allotment status is now live, and investors across India are eager to know whether they secured shares in this highly subscribed issue. After closing its bidding window on September 3, 2025, the IPO recorded overwhelming demand, making it one of the most discussed healthcare offerings of the year. With the allotment process finalized on September 4, 2025, Amanta Healthcare is set to list its shares on both BSE and NSE on September 9, 2025.
Amanta Healthcare IPO Allotment Status: How to Check
Investors can verify their Amanta Healthcare IPO allotment status through three official platforms:
- BSE Website – Select “Equity,” choose “Amanta Healthcare Ltd,” and enter your application or PAN number.
- NSE Website – Navigate to IPO bid details, select the company, and log in with your PAN and application details.
- Registrar MUFG Intime India Pvt. Ltd – On the registrar’s portal, select the company and use credentials such as PAN, DP/Client ID, or application number to confirm allotment.
This multi-channel approach ensures investors have convenient ways to check their Amanta Healthcare IPO allotment status without delays.
Subscription and Investor Response
The Amanta Healthcare IPO generated massive traction, receiving 82.61 times subscription overall by the close of Day 3. Retail investors subscribed 54.98 times, Qualified Institutional Buyers (QIBs) went for 35.86 times, and Non-Institutional Investors (NIIs) posted an extraordinary 209.42 times subscription.
Such overwhelming demand highlights the strong trust in Amanta Healthcare’s business model and growth potential in the pharmaceutical sector. Naturally, this intense interest has made the Amanta Healthcare IPO allotment status a hot topic among investors.
Grey Market Premium (GMP) Insights
As of September 4, the Grey Market Premium (GMP) for Amanta Healthcare stood at ₹8.50 per share. Based on the upper price band of ₹126, the estimated listing price is projected at ₹134.50, which translates to a 6.75% gain per share.
Though GMP is not an official indicator, it often reflects market sentiment. The positive GMP adds to the buzz around the Amanta Healthcare IPO allotment status, signaling potential listing-day gains.
Key IPO Details
- Issue Size: Fresh issue of 1 crore equity shares
- Price Band: ₹120 – ₹126 per share
- Lot Size: 119 shares
- Minimum Investment: ₹14,994 for retail investors
- Lead Manager: Beeline Capital Advisors Pvt. Ltd
- Registrar: MUFG Intime India Pvt. Ltd
The accessible lot size and moderate pricing helped attract strong retail participation, further amplifying demand and interest in the Amanta Healthcare IPO allotment status.
Company Background and Growth Potential
Founded in 1994 in Ahmedabad, Amanta Healthcare Ltd. specializes in manufacturing sterile liquid medicines, including injections, respiratory solutions, eye drops, and irrigation fluids. Its advanced Blow-Fill-Seal (BFS) technology ensures high-quality standards.
The company boasts a portfolio of more than 45 generic medicines, distributed across India and international markets. In FY25, Amanta reported revenue of ₹276 crore with a net profit of ₹10.5 crore. Its WHO-GMP-certified Gujarat facility positions it well for global expansion, which explains the high investor interest during the IPO.
Why Investors Are Tracking the Allotment Closely
The strong fundamentals of Amanta Healthcare and its consistent growth trajectory made the IPO particularly appealing. With healthcare continuing to be a defensive and growing sector, retail and institutional investors are keenly awaiting their Amanta Healthcare IPO allotment status to secure early exposure.
Moreover, the company’s adoption of advanced manufacturing technologies and a diversified product line enhances long-term scalability, adding to the appeal of this IPO.
What’s Next After Allotment?
With allotments confirmed, the next milestone is the Amanta Healthcare IPO listing on September 9, 2025. Market watchers will keep a close eye on how the shares debut against their estimated GMP. Whether investors gained allotment or not, the listing will be a major event for the pharmaceutical sector and the broader IPO market.
For readers who want to stay updated on the latest IPO news, market insights, and startup trends, visit Startup News for daily coverage.
